StreetInsider.com News Articles

Cardinal Health (CAH) PT Raised to $280 at UBS

Wed, 12 Aug 2026 09:25:35 -0400

UBS analyst Kevin Caliendo raised the price target on Cardinal Health (NYSE: CAH) to $280.00 (from $274.00) while maintaining a Buy rating.

Cardinal Health (CAH) PT Raised to $265 at Morgan Stanley

Wed, 12 Aug 2026 08:11:55 -0400

Morgan Stanley analyst Erin Wright raised the price target on Cardinal Health (NYSE: CAH) to $265.00 (from $255.00) while maintaining a Overweight rating.

Cardinal Health (CAH) PT Raised to $280 at Jefferies

Wed, 12 Aug 2026 08:07:29 -0400

Jefferies analyst Brian Tanquilut raised the price target on Cardinal Health (NYSE: CAH) to $280.00 (from $270.00) while maintaining a Buy rating.

Cardinal Health (CAH) PT Raised to $277 at Wells Fargo

Wed, 12 Aug 2026 07:05:52 -0400

Wells Fargo analyst Stephen Baxter raised the price target on Cardinal Health (NYSE: CAH) to $277.00 (from $245.00) while maintaining a Overweight rating.

Cardinal Health (CAH) PT Raised to $250 at Mizuho

Wed, 12 Aug 2026 06:37:35 -0400

(Updated - August 12, 2026 6:37 AM EDT)

Mizuho analyst Steven Valiquette raised the price target on Cardinal Health (NYSE: CAH) to $250.00 (from $240.00) while maintaining a Outperform rating.

The analyst commented: "We offer key takes from CAH's F4Q26 earnings call: 1) management reinforced our positive preview (link) that C2Q26 witnessed robust brand-to-generic conversion activity (we calculated $20+ bln of new generic launches in C2Q26); 2) For FY27 Pharma Segment outlook, management de-risked IRA-related list price reduction dynamic by suggesting fairly similar top-line impact from potential IRA-related list price cuts in FY27 as witnessed in FY26, but no earnings impact in

Cardinal Health (CAH) PT Raised to $250 at Mizuho

Wed, 12 Aug 2026 06:37:35 -0400

(Updated - August 12, 2026 6:37 AM EDT)

Mizuho analyst Steven Valiquette raised the price target on Cardinal Health (NYSE: CAH) to $250.00 (from $240.00) while maintaining a Outperform rating.

Cardinal Health (CAH) PT Raised to $274 at Baird

Wed, 12 Aug 2026 06:18:52 -0400

Baird analyst Eric Coldwell raised the price target on Cardinal Health (NYSE: CAH) to $274.00 (from $251.00) while maintaining a Outperform rating.

Increasing unusual put volume: BW CAPR CG TME BMBL ONON CHKP SIMO CGC CAH

Tue, 11 Aug 2026 09:56:53 -0400

Increasing unusual put volume: BW CAPR CG TME BMBL ONON CHKP SIMO CGC CAH

Form 10-K CARDINAL HEALTH INC For: Jun 30

Tue, 11 Aug 2026 08:58:00 -0400

si-local-file:///var/storage/secattach/20260811/26902348.html

Form 10-K CARDINAL HEALTH INC For: Jun 30

Tue, 11 Aug 2026 08:58:00 -0400

si-local-file:///var/storage/secattach/20260811/26902348.html

Cardinal Health (CAH) Tops Q4 EPS by 19c, Misses on Revenue; Offers FY27 EPS Guidance

Tue, 11 Aug 2026 06:47:00 -0400

Cardinal Health (NYSE: CAH) reported Q4 EPS of $2.60, $0.19 better than the analyst estimate of $2.41. Revenue for the quarter came in at $63.7 billion versus the consensus estimate of $65.22 billion.

GUIDANCE:

Cardinal Health sees FY2027 EPS of $12.40-$12.60, versus the consensus of $12.05.

For earnings history and earnings-related data on Cardinal Health (CAH) click here.

Cardinal Health (CAH) Tops Q4 EPS by 19c, Misses on Revenue; Offers FY27 EPS Guidance

Tue, 11 Aug 2026 06:47:00 -0400

GUIDANCE:

Cardinal Health sees FY2027 EPS of $12.40-$12.60, versus the consensus of $12.05.

For earnings history and earnings-related data on Cardinal Health (CAH) click here.

Form 8-K CARDINAL HEALTH INC For: Aug 11

Tue, 11 Aug 2026 06:47:00 -0400

si-local-file:///var/storage/secattach/20260811/26900937.html

Form 8-K CARDINAL HEALTH INC For: Aug 11

Tue, 11 Aug 2026 06:47:00 -0400

si-local-file:///var/storage/secattach/20260811/26900937.html

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance

Tue, 11 Aug 2026 06:45:00 -0400

Fourth quarter revenue increased 6% to $63.7 billion
Fourth quarter GAAP¹ diluted EPS increased 70% to $1.70
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
Incremental $350 million share repurchase completed, bringing fiscal year 2026

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance

Tue, 11 Aug 2026 06:45:00 -0400

Fourth quarter revenue increased 6% to $63.7 billion
Fourth quarter GAAP¹ diluted EPS increased 70% to $1.70
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
Incremental $350 million share repurchase completed, bringing fiscal year 2026

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance

Tue, 11 Aug 2026 06:45:00 -0400

Fourth quarter revenue increased 6% to $63.7 billion
Fourth quarter GAAP¹ diluted EPS increased 70% to $1.70
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
Incremental $350 million share repurchase completed, bringing fiscal year 2026

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance

Tue, 11 Aug 2026 06:45:00 -0400

Fourth quarter revenue increased 6% to $63.7 billion
Fourth quarter GAAP¹ diluted EPS increased 70% to $1.70
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
Incremental $350 million share repurchase completed, bringing fiscal year 2026

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance

Tue, 11 Aug 2026 06:45:00 -0400

Fourth quarter revenue increased 6% to $63.7 billion
Fourth quarter GAAP¹ diluted EPS increased 70% to $1.70
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
Incremental $350 million share repurchase completed, bringing fiscal year 2026

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance

Tue, 11 Aug 2026 06:45:00 -0400

Fourth quarter revenue increased 6% to $63.7 billion
Fourth quarter GAAP¹ diluted EPS increased 70% to $1.70
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
Incremental $350 million share repurchase completed, bringing fiscal year 2026

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance

Tue, 11 Aug 2026 06:45:00 -0400

Fourth quarter revenue increased 6% to $63.7 billion
Fourth quarter GAAP¹ diluted EPS increased 70% to $1.70
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
Incremental $350 million share repurchase completed, bringing fiscal year 2026

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance

Tue, 11 Aug 2026 06:45:00 -0400

Fourth quarter revenue increased 6% to $63.7 billion
Fourth quarter GAAP¹ diluted EPS increased 70% to $1.70
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
Incremental $350 million share repurchase completed, bringing fiscal year 2026

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance

Tue, 11 Aug 2026 06:45:00 -0400

Fourth quarter revenue increased 6% to $63.7 billion
Fourth quarter GAAP¹ diluted EPS increased 70% to $1.70
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
Incremental $350 million share repurchase completed, bringing fiscal year 2026

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance

Tue, 11 Aug 2026 06:45:00 -0400

Fourth quarter revenue increased 6% to $63.7 billion
Fourth quarter GAAP¹ diluted EPS increased 70% to $1.70
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
Incremental $350 million share repurchase completed, bringing fiscal year 2026

Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance

Tue, 11 Aug 2026 06:45:00 -0400

Fourth quarter revenue increased 6% to $63.7 billion
Fourth quarter GAAP¹ diluted EPS increased 70% to $1.70
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
Incremental $350 million share repurchase completed, bringing fiscal year 2026